Search results for "Marginal"

showing 10 items of 350 documents

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

2018

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revis…

BendamustineAdultMalemedicine.medical_specialtyPhases of clinical researchNeutropeniaGastroenterologyDisease-Free SurvivalDrug Administration ScheduleSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicineInternal medicinefirst-line therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineBendamustine HydrochlorideHumansSplenic marginal zone lymphomabendamustineAgedbusiness.industrySplenic NeoplasmsHematologyLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseLymphomaimmunochemotherapyRegimenTreatment Outcome030220 oncology & carcinogenesisbendamustine; first-line therapy; immunochemotherapy; rituximab; Splenic Marginal Zone Lymphoma; HematologySplenectomyRituximabFemaleSplenic Marginal Zone LymphomaNeoplasm Recurrence LocalbusinessRituximabFebrile neutropenia030215 immunologymedicine.drugBritish journal of haematology
researchProduct

Splenic marginal zone lymphoma.

2002

Splenic marginal zone lymphoma (SMZL) is a specific low-grade small B-cell lymphoma that is incorporated in the World Health Organization classification. Characteristic features are splenomegaly, moderate lymphocytosis with villous morphology, intrasinusoidal pattern of involvement of various organs, especially bone marrow, and relative indolent course. Tumor progression with increase of blastic forms and aggressive behavior are observed in a minority of patients. Molecular and cytogenetic studies have shown heterogeneous results probably because of the lack of standardized diagnostic criteria. To date, no definitive therapy has been established. Therapeutic options include treatment absten…

BendamustinePathologymedicine.medical_specialtyLymphoma B-CellLymphocytosismedicine.medical_treatmentImmunologySplenectomyBiochemistryImmunophenotypingDiagnosis DifferentialImmunophenotypingMedicineAnimalsHumansSplenic marginal zone lymphomabusiness.industryLymphoma Non-HodgkinSplenic NeoplasmsCell BiologyHematologymedicine.diseaseLymphomaTumor progressionCytogenetic AnalysisRituximabmedicine.symptombusinessmedicine.drugBlood
researchProduct

Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Associated With Splenic Marginal-zone Lymphoma With Low-molecular Weig…

2008

ABSTRACT Case report A 69-year-old woman with splenic marginal-zone lymphoma was admitted with progressive abdominal pain and splenomegaly as the suspected cause of pain. Rituximab treatment (375 mg/m 2 ) had been initiated on the day of admission. Abdominal computerized tomography revealed splenic infarction. Laboratory tests showed elevation of liver enzymes and creatinine, low platelet count, prolonged partial thromboplastin time, and lupus anticoagulant positivity. The diagnosis of catastrophic antiphospholipid antibody syndrome was made. Weight-adjusted low-molecular weight heparin therapy was initiated. Freedom from symptoms and normalization of liver enzymes and creatinine occurred w…

Bendamustinemedicine.medical_specialtyLymphoma B-Cellmedicine.drug_classLow molecular weight heparinAntineoplastic AgentsGastroenterologyAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineBendamustine HydrochlorideHumansMedicineSplenic marginal zone lymphomaAgedLupus anticoagulantbusiness.industrySplenic NeoplasmsAnticoagulantAntibodies MonoclonalAnticoagulantsGeneral MedicineHeparinHeparin Low-Molecular-WeightAntiphospholipid Syndromemedicine.diseaseSurgerySplenic infarctionNitrogen Mustard CompoundsFemaleRituximabRituximabbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma

2003

Among 20 cases of typical splenic marginal zone lymphoma (SMZL), two cases had blastic transformation. The genetic mechanisms underlying the morphologic transformation were investigated by comparing genetic changes in initial and blastic phases. A complex karyotype including trisomy of 3q and genomic gain of 17q22-q24 was seen in both cases at diagnosis. However, the extra copy of 3q was lost during the transformation process in both tumors. Additionally, the Karpas 1718 cell line, which was derived from a patient with transformed SMZL and carried a trisomy of 3q, also evidenced the spontaneous loss of the extra 3q during the culturing process. Other acquired abnormalities observed exclusiv…

Cancer ResearchPathologymedicine.medical_specialtyLymphoma B-CellTrisomyChromosomal translocationBiologyComplex KaryotypeTumor Cells CulturedmedicineChromosomes HumanHumansSplenic marginal zone lymphomaChromosome AberrationsLymphoma Non-HodgkinSplenic NeoplasmsHematologymedicine.diseaseTransformation (genetics)OncologyKaryotypingDisease ProgressionB-Cell Non-Hodgkin LymphomaChromosomes Human Pair 3Chromosome DeletionAbnormalityBlast CrisisTrisomyChromosomes Human Pair 17Comparative genomic hybridizationLeukemia & Lymphoma
researchProduct

Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma

2020

PI3K kinase has a prominent role in the B-cell receptor signaling. Copanlisib, a pan-PI3K inhibitor with predominant selectivity to PI3Kα and PI3Kδ, is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma, and it is currently under clinical development in other indolent lymphomas including marginal zone lymphoma (MZL). However some patients might eventually relapse because of acquired resistance and so a better understanding of resistance mechanisms is needed. Thus we generated MZL cell lines resistant to copanlisib which could help to design improved therapies

Cancer Researchchemistry.chemical_compoundOncologychemistryResistance (ecology)Marginal zone lymphomaCancer researchlymphomaPI3K inhibitorBiologyPI3K/AKT/mTOR pathwayCopanlisibEuropean Journal of Cancer
researchProduct

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

2007

Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are pr…

Cancer Researchmedicine.medical_specialtyMEDLINElymphomaComorbiditySettore MED/08 - Anatomia PatologicaAntiviral AgentsImmunophenotypingDiagnosis DifferentialAntibodies Monoclonal Murine-DerivedBone MarrowAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansCombined Modality TherapySplenic marginal zone lymphomaIntensive care medicineSplenic marginal zone lymphomaNeoplasm StagingChromosome Aberrationsbusiness.industrySplenic NeoplasmsAntibodies MonoclonalDisease ManagementLymphoma B-Cell Marginal ZoneHematologyHepatitis C ChronicPrognosismedicine.diseaseCombined Modality TherapyComorbidityLymphomaSurgeryClinical trialOncologyPractice Guidelines as TopicSplenectomyRituximabDifferential diagnosisRituximabbusinessguidelineSpleenmedicine.drugLeukemia
researchProduct

FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STU…

2019

Cancer Researchmedicine.medical_specialtyOncologybusiness.industryMedicinePhases of clinical researchHematologyGeneral MedicineSplenic marginal zone lymphomaRadiologybusinessmedicine.diseaseMinimal residual diseaseHematological Oncology
researchProduct

Measuring the CO2 shadow price for wastewater treatment: A directional distance function approach

2015

Abstract The estimation of the value of carbon emissions has become a major research and policy topic since the establishment of the Kyoto Protocol. The shadow price of CO2 provides information about the marginal abatement cost of this pollutant. It is an essential element in guiding environmental policy issues, since the CO2 shadow price can be used when fixing carbon tax rates, in environmental cost-benefit analysis and in ascertaining an initial market price for a trading system. The water industry could play an important role in the reduction of greenhouse gas (GHG) emissions. This paper estimates the shadow price of CO2 for a sample of wastewater treatment plants (WWTPs), using a param…

Carbon taxMechanical EngineeringShadow priceEnvironmental engineeringBuilding and ConstructionManagement Monitoring Policy and LawGeneral EnergyIncentiveGreenhouse gasValue (economics)Market priceEconomicsEconometricsKyoto ProtocolMarginal abatement cost
researchProduct

Castronovo di Sicilia: analisi di contesto e alcuni fatti stilizzati

2009

Castronovo di Sicilia marginalità sviluppo locale
researchProduct

Il quartiere San Berillo a Catania. Appunti per una rinascita

2023

Nell’analizzare lo sviluppo della città di Catania nei secoli, e in particolare nel secondo dopoguerra, ci si imbatte nel microcosmo di San Berillo, con la sua storia fatta di progetti mancati, pianificazioni errate e buoni propositi mai realizzati. Ancora aperta è la ferita dovuta al noto sventramento del quartiere condotto alla fine degli anni Cinquanta del secolo scorso, generatore di un vuoto urbano che solo in parte è stato colmato, trattandosi in realtà anche di un vuoto sociale e culturale. Il volume si pone nella stessa direzione positiva e propositiva di tutte quelle azioni che hanno reso pubblica e affascinante l’immagine di San Berillo: dai cortometraggi alle Web serie, dai video…

Catania San Berillo Nuovo turismo urbano Migrantour marginalitàSettore M-GGR/02 - Geografia Economico-PoliticaSettore M-GGR/01 - GeografiaCatania San Berillo New urban tourism Migrantour marginality
researchProduct